Gastroparesis treatment market

Gastroparesis Treatment Market, By Drug (Metoclopramide, Erythromycin, Domperidone, Others), By Type (Diabetic gastroparesis, Idiopathic gastroparesis, Post-surgical gastroparesis), By Route of Administration (Intravenous, Nasal, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Jul 2022
CMI5123
237 Pages
Excel & Pdf
Pharmaceutical

Summary

Gastroparesis affects the spontaneous movement of muscles (motility) in the stomach. Gastroparesis can interfere with normal digestion and cause nausea, vomiting, and abdominal pain. It causes problems with blood sugar levels and nutrition. Dietary changes and medical treatment can help control the condition. Medications such as domperidone, erythromycin, anti-emetics, and others are used to treat gastroparesis condition.

The global gastroparesis treatment market is estimated to be valued at US$ 8,061.9 million in 2022 and expected to exhibit a CAGR of 3.6% during the forecast period (2022-2030).

Figure 1. Global Gastroparesis Treatment Market in Terms of Value (US$ million), By Region, 2022

An increase in the number of pipeline products is estimated to drive the global gastroparesis treatment market growth during the forecast period.

The drug candidates which are developed and investigated for the treatment of gastroparesis have shown promising results in clinical trials. As a result, regulatory authorities such as the U.S. Food and Drug Administration (FDA) are awarding designations to the drug candidates. This is contribute to increase in number of pipeline products and thereby drive the growth of market. For instance, in February 2020, CinDome Pharma, Inc., a biopharmaceutical company, initiated a phase 2 clinical trial study to investigate the effect of oral CIN-102 (Deuterated domperidone (deudomperidone)) on gastric emptying and antral contractility in adults with diabetic gastroparesis.

Gastroparesis Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 8,061.9 Mn
Historical Data for:	2017 to 2021	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	3.6%	2030 Value Projection:	US$ 10,726.0 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug: Metoclopramide, Erythromycin, Domperidone, Others By Type: Diabetic gastroparesis, Idiopathic gastroparesis, Post-surgical gastroparesis By Route of Administration: Intravenous, Nasal, Oral By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Processa Pharmaceuticals, Inc., EVOKE PHARMA , Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals
Growth Drivers:	An increase in the number of pipeline products The development of novel treatment
Restraints & Challenges:	Side effects associated with gastroparesis drugs

Figure 2. Global Gastroparesis Treatment Market Share (%), By Drug, 2022

The development of novel treatment is anticipated to propel the global gastroparesis treatment market growth over the forecast period.

An increase in the prevalence of gastroparesis leads to an increase in the demand for novel treatment products. For instance, , in January 2018, according to National Institute of Diabetes and Digestive and Kidney Diseases, out of 100,000 people, about 10 men and about 40 women have gastroparesis in United States. Thus, developing newer products will create a lucrative opportunity for market players and drive the market growth. For instance, in November 2016, researchers at Emory University School of Medicine demonstrated the positive short-term outcomes for gastric per oral endoscopic pyloromyotomy or G-POEM, a minimally invasive procedure. The novel treatment showed significant improvement in symptoms of patients with gastroparesis (diabetic gastroparesis and idiopathic gastroparesis). Novel approaches/agents under evaluation for gastroparesis, include the prokinetic ghrelin agonist relamorelin, the prokinetic serotonergic agents velusetrag and prucalopride, the anti-emetic aprepitant, and per-endoscopic pyloric myotomy procedures.

Global Gastroparesis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Coronavirus disease (COVID-19) is a disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which commonly has symptoms such as fever, cough, and dyspnea
According to the 2020 annual report of EVOKE PHARMA, a biotechnology company, due to the restrictions imposed as a result of the COVID-19 pandemic, such as lockdown, its sales force has been restricted from conducting in-person interactions with certain physicians and customers. It has been restricted to conduct educational and promotional activities for Gimoti, indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The continued spread of the COVID-19 and the measures taken by the governments of countries affected disrupted the raw material supply chain and the manufacturing or shipment of Gimoti for commercial sale which could have an adverse effect on the business, financial condition, and results of operations.

Global Gastroparesis Treatment Market: Restraint

Side effects associated with gastroparesis drugs are likely to hamper the market growth. Gastroparesis medications will vary in their side effects depending on the medication, dose, and patient’s other medical conditions. Fatigue, drowsiness, sedation, anxiety, and restlessness are some of the most prevalent side effects linked with prokinetics.

Key Players

Major players operating in the global gastroparesis treatment market include Processa Pharmaceuticals, Inc., EVOKE PHARMA, Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals.

Table of Content

Table of Contents

*Browse 27 market data tables and 31 figures on "Global Gastroparesis Treatment Market” - Global forecast to 2028

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global gastroparesis treatment market during the forecast period (2022-2030)?

The global gastroparesis treatment market is estimated to be valued at US$ 8,061.9 million in 2022 and expected to exhibit a CAGR of 3.6% between 2022 and 2030.

What are the major factors driving the global market growth?

Factors such as strong pipeline products are projected to boost the market growth over the forecast period.

Which is the leading drug segment in the market?

The metoclopramide segment is expected to hold a major market share in the market in 2022.

What are the key factors hampering the growth of the market?

The major factors hampering the growth of the market include side effects related to gastroparesis drugs.

Which are the major players operating in the market?

Major players operating in the market include Processa Pharmaceuticals, Inc., EVOKE PHARMA, Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals.